甲氨蝶呤增加类风湿关节炎患者血清钙水平:印度尼西亚一家转诊医院的回顾性研究

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2023-01-01 DOI:10.1016/j.curtheres.2023.100726

Dika P. Destiani M. Pharm , Vida M. Utami B. Pharm , Syifa Farhanah B. Pharm , Sofa D. Alfian PhD , Sumartini Dewi PhD Prof. , Syed A.S. Sulaiman PhD Prof. , Rizky Abdulah PhD

{"title":"甲氨蝶呤增加类风湿关节炎患者血清钙水平:印度尼西亚一家转诊医院的回顾性研究","authors":"Dika P. Destiani M. Pharm , Vida M. Utami B. Pharm , Syifa Farhanah B. Pharm , Sofa D. Alfian PhD , Sumartini Dewi PhD Prof. , Syed A.S. Sulaiman PhD Prof. , Rizky Abdulah PhD","doi":"10.1016/j.curtheres.2023.100726","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Rheumatoid arthritis (RA) is a significant issue, particularly in bone health problems, because it can prolong diseases like secondary osteoporosis. Subsequently, the anchor of drug therapy for RA is methotrexate (MTX), which also has the potential to reduce the risk of secondary osteoporosis.</p></div><div><h3>Objective</h3><p>This study aims to examine the effect of MTX on calcium levels, an important parameter for monitoring bone health and the risk of secondary osteoporosis in patients with RA.</p></div><div><h3>Methods</h3><p>A retrospective study was carried out by collecting data from the medical records of patients, which included demographic and patient characteristics, treatment data (drug and dosage), duration of treatment, and calcium levels. All patients were diagnosed with RA and fell within the age range of 18 to 59 years. Additionally, the effectiveness of MTX therapy was compared with other treatments, categorizing patient data accordingly. Statistical analyses, such as χ<sup>2</sup> and ordinal regression, using IBM-SPSS Statistics version 25 (IBM-SPSS Inc, Armonk, New York) were used to establish associations between MTX treatment and calcium levels, reporting odds ratio and 95% CI values.</p></div><div><h3>Results</h3><p>The data consisted of 123 patients with RA, comprising 99 who had a history of MTX use for more than 6 months and 24 who either did not use MTX or used it for <6 months. The majority of patients were women and their ages ranged between 40 and 59 years. MTX monotherapy was the most used with a dose range of 7.5 to 15 mg. Furthermore, this study observed that patients treated with MTX between 7.5 and 15 mg have lower serum calcium levels than those who received 17.5 to 25 mg (<em>P</em> = 0.022; odds ratio = 5.663; 95% CI, 0.251–3.218). Most patients with RA using MTX maintained normal calcium levels. No significant differences were observed between single MTX therapy and combination therapy.</p></div><div><h3>Conclusions</h3><p>Although further investigation is needed, this study showed the potential properties of MTX in maintaining patients’ serum calcium levels, which may help to reduce the risk of secondary osteoporosis in patients with RA.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100726"},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X23000358/pdfft?md5=9e11e420b0006eab491235a7f4a5667d&pid=1-s2.0-S0011393X23000358-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Methotrexate Increases Serum Calcium Levels in Patients with Rheumatoid Arthritis: A Retrospective Study at a Referral Hospital in Indonesia\",\"authors\":\"Dika P. Destiani M. Pharm , Vida M. Utami B. Pharm , Syifa Farhanah B. Pharm , Sofa D. Alfian PhD , Sumartini Dewi PhD Prof. , Syed A.S. Sulaiman PhD Prof. , Rizky Abdulah PhD\",\"doi\":\"10.1016/j.curtheres.2023.100726\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Rheumatoid arthritis (RA) is a significant issue, particularly in bone health problems, because it can prolong diseases like secondary osteoporosis. Subsequently, the anchor of drug therapy for RA is methotrexate (MTX), which also has the potential to reduce the risk of secondary osteoporosis.</p></div><div><h3>Objective</h3><p>This study aims to examine the effect of MTX on calcium levels, an important parameter for monitoring bone health and the risk of secondary osteoporosis in patients with RA.</p></div><div><h3>Methods</h3><p>A retrospective study was carried out by collecting data from the medical records of patients, which included demographic and patient characteristics, treatment data (drug and dosage), duration of treatment, and calcium levels. All patients were diagnosed with RA and fell within the age range of 18 to 59 years. Additionally, the effectiveness of MTX therapy was compared with other treatments, categorizing patient data accordingly. Statistical analyses, such as χ<sup>2</sup> and ordinal regression, using IBM-SPSS Statistics version 25 (IBM-SPSS Inc, Armonk, New York) were used to establish associations between MTX treatment and calcium levels, reporting odds ratio and 95% CI values.</p></div><div><h3>Results</h3><p>The data consisted of 123 patients with RA, comprising 99 who had a history of MTX use for more than 6 months and 24 who either did not use MTX or used it for <6 months. The majority of patients were women and their ages ranged between 40 and 59 years. MTX monotherapy was the most used with a dose range of 7.5 to 15 mg. Furthermore, this study observed that patients treated with MTX between 7.5 and 15 mg have lower serum calcium levels than those who received 17.5 to 25 mg (<em>P</em> = 0.022; odds ratio = 5.663; 95% CI, 0.251–3.218). Most patients with RA using MTX maintained normal calcium levels. No significant differences were observed between single MTX therapy and combination therapy.</p></div><div><h3>Conclusions</h3><p>Although further investigation is needed, this study showed the potential properties of MTX in maintaining patients’ serum calcium levels, which may help to reduce the risk of secondary osteoporosis in patients with RA.</p></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"99 \",\"pages\":\"Article 100726\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0011393X23000358/pdfft?md5=9e11e420b0006eab491235a7f4a5667d&pid=1-s2.0-S0011393X23000358-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X23000358\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000358","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

类风湿性关节炎(RA)是一个重要的问题，特别是在骨骼健康问题中，因为它可以延长继发性骨质疏松症等疾病。随后，RA药物治疗的锚点是甲氨蝶呤(MTX)，它也有可能降低继发性骨质疏松症的风险。目的探讨甲氨蝶呤对类风湿关节炎患者钙水平的影响，钙水平是监测骨骼健康和继发性骨质疏松风险的重要指标。方法通过收集患者的病历资料进行回顾性研究，包括人口统计学和患者特征、治疗资料(药物和剂量)、治疗时间、钙水平等。所有患者均被诊断为类风湿性关节炎，年龄在18至59岁之间。此外，将MTX治疗的有效性与其他治疗进行比较，并对患者数据进行相应的分类。使用IBM-SPSS Statistics version 25 (IBM-SPSS Inc .， Armonk, New York)进行统计学分析，如χ2和序数回归，以建立MTX治疗与钙水平之间的关联，报告优势比和95% CI值。结果数据包括123例RA患者，其中99例使用MTX超过6个月，24例未使用MTX或使用MTX 6个月。大多数患者为女性，年龄在40至59岁之间。MTX单药治疗是最常用的，剂量范围为7.5至15mg。此外，本研究观察到，接受7.5 - 15 mg MTX治疗的患者血清钙水平低于接受17.5 - 25 mg MTX治疗的患者(P = 0.022;优势比 = 5.663;95% ci, 0.251-3.218)。大多数使用MTX的RA患者维持正常的钙水平。单次甲氨蝶呤治疗与联合治疗无显著差异。结论虽然需要进一步的研究，但本研究显示了MTX在维持患者血清钙水平方面的潜在特性，这可能有助于降低RA患者继发性骨质疏松症的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Methotrexate Increases Serum Calcium Levels in Patients with Rheumatoid Arthritis: A Retrospective Study at a Referral Hospital in Indonesia

Background

Rheumatoid arthritis (RA) is a significant issue, particularly in bone health problems, because it can prolong diseases like secondary osteoporosis. Subsequently, the anchor of drug therapy for RA is methotrexate (MTX), which also has the potential to reduce the risk of secondary osteoporosis.

Objective

This study aims to examine the effect of MTX on calcium levels, an important parameter for monitoring bone health and the risk of secondary osteoporosis in patients with RA.

Methods

A retrospective study was carried out by collecting data from the medical records of patients, which included demographic and patient characteristics, treatment data (drug and dosage), duration of treatment, and calcium levels. All patients were diagnosed with RA and fell within the age range of 18 to 59 years. Additionally, the effectiveness of MTX therapy was compared with other treatments, categorizing patient data accordingly. Statistical analyses, such as χ² and ordinal regression, using IBM-SPSS Statistics version 25 (IBM-SPSS Inc, Armonk, New York) were used to establish associations between MTX treatment and calcium levels, reporting odds ratio and 95% CI values.

Results

The data consisted of 123 patients with RA, comprising 99 who had a history of MTX use for more than 6 months and 24 who either did not use MTX or used it for <6 months. The majority of patients were women and their ages ranged between 40 and 59 years. MTX monotherapy was the most used with a dose range of 7.5 to 15 mg. Furthermore, this study observed that patients treated with MTX between 7.5 and 15 mg have lower serum calcium levels than those who received 17.5 to 25 mg (P = 0.022; odds ratio = 5.663; 95% CI, 0.251–3.218). Most patients with RA using MTX maintained normal calcium levels. No significant differences were observed between single MTX therapy and combination therapy.

Conclusions

Although further investigation is needed, this study showed the potential properties of MTX in maintaining patients’ serum calcium levels, which may help to reduce the risk of secondary osteoporosis in patients with RA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.